Citations

Showing 10 of 108083 citations.

Quantitative magnetic resonance imaging phantoms: A review and the need for a system phantom
Keenan, Kathryn E. , Ainslie, Maureen, Barker, Alex J. , Boss, Michael A. , Cecil, Kim M. , Charles, Cecil, Chenevert, Thomas L. , Clarke, L., Evelhoch, Jeffrey L., Finn, Paul, Gembris, Daniel, Gunter, Jeffrey L. , Hill, David , Jack, Clifford R. , Liu, Guoying , Sharma, Samir D. , Steckner, Michael , Stupic, Karl F. , Trzasko, Joshua D. , Yuan, Chun , Zheng, Jie , Jack, Clifford R , Barker, Alex J , Keenan, Kathryn E , Boss, Michael A , Jackson, Edward F. , Russek, Stephen E.

Mayo Clinic

Magnetic Resonance in Medicine | October 30, 2017 | Volume: 79 | Issue: 1 | Pages: 48-61

10.1002/mrm.26982 | PMID 29083101 Get It

The MRI community is using quantitative mapping techniques to complement qualitative imaging. For quantitative imaging to reach its full potential, it is necessary to analyze measurements across systems and longitudinally. Clinical use of quantitative imaging can be facilitated through adoption and use of a standard system phantom, a calibration/standard reference object, to assess the performance of an MRI machine. The International Society of Magnetic Resonance in Medicine AdHoc Committee on Standards for Quantitative Magnetic Resonance was established in February 2007 to facilitate the expansion of MRI as a mainstream modality for multi‐institutional measurements, including, among other things, multicenter trials. The goal of the Standards for Quantitative Magnetic Resonance committee was to provide a framework to ensure that quantitative measures derived from MR data are comparable over time, between subjects, between sites, and between vendors. This paper, written by members of the Standards for Quantitative Magnetic Resonance committee, reviews standardization attempts and then details the need, requirements, and implementation plan for a standard system phantom for quantitative MRI. In addition, application‐specific phantoms and implementation of quantitative MRI are reviewed. Magn Reson Med 79:48–61, 2018. © 2017 International Society for Magnetic Resonance in Medicine.
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis
Puri, Puneet , Liangpunsakul, Suthat , Christensen, Jeffrey E. , Shah, Vijay H. , Kamath, Patrick S. , Katz, Barry P., Yu, Qigui , Kumar, Divya P. , Mirshahi, Faridoddin , Radaeva, Svetlana , Chalasani, Naga , Crabb, David W. , Gores, Gregory J. , Walker, Sue , Comerford, Megan , Borst, Andrew J. , Sanyal, Arun J.

Mayo Clinic

Hepatology | October 30, 2017 | Volume: 67 | Issue: 4 | Pages: 1284-1302

10.1002/hep.29623 | PMID 29083504 Get It

Intestinal dysbiosis is implicated in alcoholic hepatitis (AH). However, changes in the circulating microbiome, its association with the presence and severity of AH, and its functional relevance in AH is unknown. Qualitative and quantitative assessment of changes in the circulating microbiome were performed by sequencing bacterial DNA in subjects with moderate AH (MAH) (n = 18) or severe AH (SAH) (n = 19). These data were compared with heavy drinking controls (HDCs) without obvious liver disease (n = 19) and non–alcohol‐consuming controls (NACs, n = 20). The data were related to endotoxin levels and markers of monocyte activation. Linear discriminant analysis effect size (LEfSe) analysis, inferred metagenomics, and predictive functional analysis using PICRUSt were performed. There was a significant increase in 16S copies/ng DNA both in MAH ( P < 0.01) and SAH ( P < 0.001) subjects. Compared with NACs, the relative abundance of phylum Bacteroidetes was significantly decreased in HDCs, MAH, and SAH ( P < 0.001). In contrast, all alcohol‐consuming groups had enrichment with Fusobacteria ; this was greatest for HDCs and decreased progressively in MAH and SAH. Subjects with SAH had significantly higher endotoxemia ( P = 0.01). Compared with alcohol‐consuming groups, predictive functional metagenomics indicated an enrichment of bacteria with genes related to methanogenesis and denitrification. Furthermore, both HDCs and SAH showed activation of a type III secretion system that has been linked to gram‐negative bacterial virulence. Metagenomics in SAH versus NACs predicted increased isoprenoid synthesis via mevalonate and anthranilate degradation, known modulators of gram‐positive bacterial growth and biofilm production, respectively. Conclusion: Heavy alcohol consumption appears to be the primary driver of changes in the circulating microbiome associated with a shift in its inferred metabolic functions. (H epatology 2018;67:1284‐1302).
Therapeutic plasma exchange causing (not curing) hemolysis
Graham, Brendan C. , Burgstaler, Edwin A. , Winters, Jeffrey L. , Winters, Jeffrey L

Mayo Clinic

Journal of Clinical Apheresis | October 30, 2017 | Volume: 33 | Issue: 3 | Pages: 393-395

10.1002/jca.21596 | PMID 29083046 Get It

The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials
Mendoza, Tito R. , Dueck, Amylou C. , Ma, Haijun , Zhang, J., Qian, Yi , Cleeland, Charles S. , Dueck, A. C. , Mendoza, Tito , Shi, Qiuling

Mayo Clinic

European Journal of Pain | October 30, 2017 | Volume: 22 | Issue: 3 | Pages: 565-571

10.1002/ejp.1139 | PMID 29082574 Get It

AbstractBackgroundWe aimed to provide a simple, descriptive health‐status profile for cancer patients with bone metastases, based on the EuroQol EQ‐5D, a tool commonly used to measure health utility scores, and to evaluate its association with the Brief Pain Inventory (BPI), a legacy pain‐assessment tool. Although pain is one of five health‐status dimensions measured by the EQ‐5D, our understanding of how pain relates to the other EQ‐5D dimensions is limited.MethodsWe derived data from 5500 patients with bone metastases who completed the EQ‐5D and BPI. Regression analyses examined how BPI severity and interference scores correlated with EQ‐5D utility scores and how BPI items associated with EQ‐5D items, for the entire sample and by disease‐type subgroup.ResultsRegardless of cancer site, the percentage of patients reporting moderate/severe problems in each of the five EQ‐5D dimensions were pain/discomfort, 78%; usual activities, 58%; mobility, 55%; anxiety/depression, 57%; and self‐care, 26%. BPI pain interference explained more of the variability in the EQ‐5D utility scores than did pain severity (R2 = 41% vs. 34%). BPI worst pain, average pain, pain now, interference with general activity, and interference with work significantly predicted EQ‐5D pain/discomfort, with odds ratio estimates <1.ConclusionsPain/discomfort was the worst‐rated dimension of the EQ‐5D in this population, but the relationship of this item to BPI pain severity was modest, suggesting that the single pain item of the EQ‐5D may be of limited utility in studies for which pain is an endpoint.SignificanceHealth‐status dimensions include more than pain. We examine the contribution of pain severity and pain‐related functional interference in determining the health status of cancer patients with bone metastases. The pain dimension from a health‐status measure may be an inadequate metric in clinical trials/clinical practice when pain is an important outcome.
Addressing Pediatric Obesity in Clinic
Ahanogbe, Isabella, Thurston, McKennan J., White, Richard O. , Roche‐Green, Alva, Pujalte, George G.A. , Roche-Green, Alva

Mayo Clinic

Global Pediatric Health | October 30, 2017 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/2333794x17736971 | PMID 29119130 Get It

There is an epidemic of pediatric obesity in the United States. In most cases, there is an excess in the amount of calories consumed, compared with the amount of calories expended. Numerous body systems are affected by pediatric obesity, with complications varying between boys and girls. Behavioral, genetic, and environmental factors affect the ability of children to avoid becoming obese. Primary care physicians should screen for obesity in children as much as possible. Associated risk factors for obesity should be uncovered. Methods of preventing obesity should be discussed routinely with children and their families. Healthy dietary habits are key, and so are family-oriented interventions, such as eating together at dinnertime. One hour of moderate to vigorous activity daily is recommended for children and adolescents. While pediatric bariatric surgery is an option, there are also numerous nonpharmacological and pharmacological measures available as management for pediatric obesity. Family-based approaches, such as reducing screen time, have been very successful. Non–weight-bearing exercises also help children and adolescents expend calories without causing injury to themselves. Family availability, activity preference, and developmental levels should all be considerations when managing pediatric obesity. Motivational interviewing may also be helpful, especially when customized for each specific patient and family. Clinicians will play an increasing role in terms of identifying, treating, and preventing pediatric obesity; measures that can be done in the clinic should be considered more and more.
Cognitive impairment in progressive supranuclear palsy is associated with tau burden
Koga, Shunsuke , Parks, Adam , Kasanuki, Koji , Josephs, Keith A. , Ahlskog, J. Eric , Uitti, Ryan J. , Graff‐Radford, Neill R. , Gerpen, Jay A. van, Rademakers, Rosa , Baker, Matthew C, Van Gerpen, Jay A, Koga, Shunsuke , Sánchez-Contreras, Mónica , Baker, Matthew , Wszołek, Zbigniew K. , Dickson, Dennis W.

Mayo Clinic

Movement Disorders | October 30, 2017 | Volume: 32 | Issue: 12 | Pages: 1772-1779

10.1002/mds.27198 | PMID 29082658 Get It

Abstract Background Cognitive impairment is one of the core features of progressive supranuclear palsy. This study aimed to clarify the profile of cognitive impairment and its underlying pathology in progressive supranuclear palsy. Methods We retrospectively reviewed medical records to evaluate the pattern and severity of cognitive impairment in 121 autopsy‐confirmed progressive supranuclear palsy patients. A subset of 37 patients underwent neuropsychological evaluation as part of their clinical workup. The burden of progressive supranuclear palsy‐related tau pathology (neurofibrillary tangles/pretangles, coiled bodies, tufted astrocytes, and threads) was semiquantitatively scored in 20 vulnerable brain regions. Concurrent pathologies potentially associated with cognitive impairment, such as Alzheimer's‐type pathology, were also assessed. To evaluate possible genetic risk factors for cognitive impairment, genetic analysis for APOE and MAPT was performed. Results Ninety patients (74%) had documented cognitive impairment based on neurologic evaluation. In a subgroup with neuropsychological testing (n = 37), executive functioning was the most severely impaired cognitive domain. A global cognitive impairment index (Spearman's rho, −0.49; P = 0.005) and executive functioning were negatively correlated with total tau burden (Spearman's rho, −0.51; P = 0.003), but not correlated with the Alzheimer's‐type pathology. APOE ɛ4 carriers had more severe amyloid pathology, but total tau burden and a global cognitive impairment index did not differ from APOE ɛ4 noncarriers. Conclusion Cognitive impairment in progressive supranuclear palsy, most notably executive dysfunction, is associated with severity of progressive supranuclear palsy‐related tau pathology. © 2017 International Parkinson and Movement Disorder Society
ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
Reese, Jordan , Bruinsma, Elizabeth S. , Negron, Vivian , Hawse, John R. , Reese, Jordan M, Monroe, David G. , Ingle, James N. , Suman, Vera J. , Goetz, Matthew P.

Mayo Clinic

Oncotarget | October 29, 2017 | Volume: 8 | Issue: 57 | Pages: 96506-96521

10.18632/oncotarget.21787 | PMID 29228549 Get It

Large-vessel giant cell arteritis: diagnosis, monitoring and management
Matteson, Eric L. , Warrington, Kenneth J. , Warrington, Kenneth J , Koster, Matthew J.

Mayo Clinic

Rheumatology | October 28, 2017 | Volume: 57 | Issue: suppl_2 | Pages: ii32-ii42

10.1093/rheumatology/kex424 | PMID 29982778 Get It

OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia
Petrucelli, Leonard , Strong, Michael J. , Gendron, Tania F. , Strong, Michael J , Farhan, Sali M K , Hegele, Robert Alexander

Mayo Clinic

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics | October 28, 2017 | Volume: 177 | Issue: 1 | Pages: 75-85

10.1002/ajmg.b.32606 | PMID 29080331 Get It

We have ascertained two families affected with familial amyotrophic lateral sclerosis (ALS) in which they both carry a hexanucleotide repeat expansion in the C9orf72 gene, specifically in individuals who also presented with frontotemporal dementia (FTD) or behavioral variant FTD (bvFTD). While some reports attribute this phenotypic heterogeneity to the C9orf72 expansion alone, we screened for additional genetic variation in known ALS‐FTD genes that may also contribute to or modify the phenotypes. We performed genetic testing consisting of C9orf72 hexanucleotide expansion, ATXN2 polyglutamine (polyQ) expansion, and targeted next generation sequencing using the ONDRISeq, a gene panel consisting of 80 genes known to be associated with neurodegenerative diseases such as ALS, FTD, Alzheimer's disease, Parkinson's disease, and vascular cognitive impairment. In addition to the C9orf72 expansion, we observed an ATXN2 polyQ intermediate length expansion, and OPTN p.Met468Arg in patients who exhibited ALS and FTD or bvFTD. We conclude that the C9orf72 expansion likely explains much of the ALS‐FTD phenotype; however, inheritance of these additional variants likely modifies the disease course and may provide further evidence for biologically relevant oligogenic inheritance in ALS.